Cytori Licensee Kerastem Tech Expands Phase II Trial Of Early Baldness

(RTTNews) - Cytori Therapeutics, Inc. (CYTX) Thursday said that its licensee Kerastem Technologies, LLC, has expanded STYLE, its US phase II clinical trial. Kerastem said it has added new trial sites in New York and New Jersey to complement the currently enrolling sites in Los Angeles and Miami. The trial in phase II is to investigate early stage female and male pattern hair loss or alopecia.

Marc Hedrick, president & CEO of Cytori said, "If this trial is successful, we believe the Kerastem/Cytori partnership could provide effective treatment for people dealing with hair loss and create a significant new revenue source for Cytori, creating value for our stockholders."

STYLE is a randomized, blinded, and controlled investigation of Kerastem it was approved to enroll up to 70 patients at up to eight centers within the United States.